Advances With 225Ac-DOTATATE Targeted Alpha Therapy in Somatostatin Receptor Positive Neuroendocrine Tumors.
Sign Up to like & getrecommendations! Published in 2025 at "Seminars in nuclear medicine"
DOI: 10.1053/j.semnuclmed.2025.06.008
Abstract: 225Ac-DOTATATE-based targeted alpha therapy (TAT) is emerging as a transformative option in the management of advanced, well-differentiated, somatostatin receptor (SSTR)-positive neuroendocrine tumors (NETs), particularly in patients refractory to conventional β-emitter peptide receptor radionuclide therapy (PRRT).… read more here.
Keywords: receptor; therapy; 225ac dotatate; alpha therapy ... See more keywords